CEO Morten Henneveld and CFO Anders Svensson present the Q1 report for 2024 and answer questions from the viewers.
Arkiv: Webcasts
Integrum – Q3 Presentation 2023
AlzeCure Pharma – Advances in the treatment of Alzheimer’s disease – Small molecule gamma-secretase modulators (GSMs) as promising disease-modifying treatments
15:00 CET / 09:00am ET
Program:
15:00 Welcome address, agenda & company overview – Martin Jönsson, CEO, AlzeCure
15:10 Alzheimer’s and amyloid hypothesis – Henrik Zetterberg1, MD, PhD, Gothenburg Univ. & University College London
15:50 Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure
16:05 Q&A
16:25 Concluding remarks – Martin Jönsson, CEO, AlzeCure
Freemelt – Q4 Interim report
Rottneros – Q1 Presentation 2024
CEO Lennart Eberleh and CFO Monica Pasanen will be presenting the Q1 report for 2024 and answering questions during the Q&A.